SR0716 103RD GENERAL ASSEMBLY

SR0716 LRB103 38308 LAW 68443 r

SENATE RESOLUTION

WHEREAS, Feline infectious peritonitis (FIP) is a viral disease of cats caused by certain strains of a virus called the feline coronavirus; and

WHEREAS, Until recently, FIP was considered to be a non-treatable disease; and

WHEREAS, Once a cat develops clinical FIP, the disease is usually progressive and almost always fatal without the use of a therapy that has recently become available but has yet to be approved by the Food and Drug Administration (FDA) to treat FIP in cats; and

WHEREAS, Two drugs, GS-5734, also known as remdesivir, and GS-441524, a metabolite of remdesivir, showed very promising results, generating cure rates between 80% and 100% in both artificially and naturally infected cats; and

WHEREAS, Studies in both the laboratory and in client-owned cats with naturally occurring FIP suggest that GS-441524 may ultimately prove to be an effective treatment option for the effusive form of FIP; however, GS-441524 is currently not FDA-approved; and

WHEREAS, While a number of sources offer GS-441524 for sale, reports suggest that the products being provided by some of these sources vary widely in both accuracy of reported drug concentration and purity; and

WHEREAS, While remdesivir was pursued as a treatment for severely ill COVID-19 patients, the company that developed it did not seek approval for the other molecule as a veterinary drug, fearing that any undesirable effects discovered for that molecule could hinder approval of remdesivir for human use; therefore, be it

RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we encourage the U.S. Food and Drug Administration (FDA) to approve GS-441524 and remdesivir to treat feline infectious peritonitis (FIP) in cats; and be it further

RESOLVED, That suitable copies of this resolution be delivered to all members of the Illinois Congressional Delegation and the Food and Drug Administration.